June 1, 2020 / 12:32 PM / a month ago

BRIEF-FDA Accepts Shionogi's Supplemental New Drug Application With Priority Review For Fetroja

June 1 (Reuters) - Shionogi & Co Ltd:

* FDA ACCEPTS SHIONOGI’S SUPPLEMENTAL NEW DRUG APPLICATION WITH PRIORITY REVIEW FOR FETROJA® (CEFIDEROCOL) FOR THE TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA AND VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA

* SHIONOGI & CO LTD -U.S. FDA ACCEPTED CO’S SNDA FOR FETROJA & GRANTED PRIORITY REVIEW DESIGNATION WITH PDUFA DATE OF SEPTEMBER 27, 2020 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below